Submit Deal

TRAVERE THERAPEUTICS (BILE ACID PRODUCT PORTFOLIO)

Summary

Travere’s bile acid product portfolio includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 367 M

Avg. Deal Size£ 367 M

Market Context

Sort

evercore

HQ - New York

financial advisors (1)

1 Shared Deal

1 Opposite

£ 367 M

Total Value

gibson dunn & crutcher

HQ - Los Angeles

legal advisors (1)

1 Shared Deal

1 Opposite

£ 367 M

Total Value

morgan stanley

HQ - New York

financial advisors (1)

1 Shared Deal

1 Opposite

£ 367 M

Total Value

latham & watkins

HQ - New York, United States

legal advisors (1)

1 Shared Deal

1 Opposite

£ 367 M

Total Value

argot partners

pr advisors (1)

1 Shared Deal

1 Opposite

£ 367 M

Total Value

lazard

HQ - New York

financial advisors (1)

1 Shared Deal

1 Along

£ 367 M

Total Value

cooley

HQ - Palo Alto

legal advisors (1)

1 Shared Deal

1 Along

£ 367 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy